A United States based biotechnology company Novavax announced on Tuesday the start of human trials in Australia of a vaccine for the Coronavirus with hopes of releasing a proven vaccine this year.
Novavax has begun the first phase of trial in which 131 volunteers in the cities of Brisbane and Melburne will test the safety of the COVID19 vaccine and look for early signs of the vaccine's effectiveness, Dr Gregory Glenn Company's research chief said.
We are in parallel making doses, making a vaccine in anticipation that we will be able to show it's effectiveness and be able to start deploying it by the end of 2020, Mr Glennsaid a virtual press conference in Melbourne from Novavax headquarters in Maryland.
About a numbers of experimental vaccines are in early stages of testing, mostly in China, Europe and United States. Still it is not clear that any of the experiment will prove safe and effective. But many of the experiment work in diffrent ways, and are made with different technologies, increasing the odds that at least one approach might succeed.
Most of the experiments in the pipeline aim to train the human immune system to recognise the spike protein that studs the Sars CoV 2 outer surface, priming the body to react if it ever encountered the COVID19 infection. Some candidates are made using just the genetic code for that protein, and other use a harmless virus to deliver the protein producing information. Still, other COVID19 vaccine candidates are more old fashioned, made with the killed whole virus.
Novavax adds another new kind to that list, that's called a recombinant vaccine. Novavx used genetic engineering to grow harmless copies of the Sars CoV 2 protein in giant vats of insect cells in a labratory. Researchers extracted and purified the protein, and packaged it into the virus sized nanoparticles.
The way we make the vaccine is we never touch the virus, Novavax told the associated press last month. But ultimately it looks like a virus to the immune system. This process is same process that Novavax used to create a nanoparticle flu vaccine that recently passed late stage testing.